Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis

  • Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
  • NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
/by

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
arcticnovartis

  • ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1
  • Following switch to Kesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse rates (ARR) were observed1
/by

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
arcticnovartis

 

/by

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
arcticnovartis

 

/by

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
arcticnovartis

  • V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1
  • 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT1
/by

New Novartis ESC data highlights strength of cardiovascular portfolio

New Novartis ESC data highlights strength of cardiovascular portfolio
arcticnovartis

PRESS RELEASE

/by

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
arcticnovartis

/by

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by